European Journal of Preventive Cardiology (EJPC)Interplay of HDL Cholesterol and apoB and the Risk of Incident Atherosclerotic Cardiovascular Disease in UK Biobank

ℹ️ Observational Association Only Evidence

This UK Biobank analysis examined whether HDL-C contributes information beyond apoB and modifies its association with incident ASCVD. Adjusted models used residual analysis to separate each marker’s association from their shared variation. Higher HDL-C remained associated with lower risk, while higher apoB remained associated with greater risk. A significant interaction suggested a weaker apoB–risk relationship at higher HDL-C. These findings concern risk associations, not treatment response, and do not establish that HDL-C itself is protective.

Clinical Considerations

• Per standard deviation, apoB had an adjusted HR of 1.16 (95% CI, 1.15–1.18); HDL-C residual had an HR of 0.85 (0.84–0.87).
• The apoB–HDL-C interaction HR was 0.95 (95% CI, 0.93–0.96), with consistent findings in men and women.
• Triglyceride adjustment did not materially alter these associations; this does not establish that triglyceride-rich lipoproteins lack clinical relevance.
• Participants with triglycerides ≥250 mg/dL were excluded, limiting applicability to higher-triglyceride populations.
• HDL-C measures cholesterol mass, not HDL particle function; proposed protective mechanisms were not directly tested.
• Substantial exclusions, cohort representativeness, and residual metabolic or inflammatory confounding limit generalizability and causal interpretation.

Practice Applications

• Recognize that independent association does not establish improved clinical prediction or validate a new risk-assessment tool.
• Avoid interpreting high HDL-C as a reason to disregard elevated apoB or reduce indicated lipid-lowering treatment.
• Distinguish naturally observed HDL-C levels from pharmacological HDL-C raising; this analysis does not establish a therapeutic target.